CASSIPHARMA
Board
1 director, no change since 2023Director (not named in the articles), permanent representative
appointed by deed of 20-02-2023
term without a fixed end
earlier manager, until 20-02-2023
also on the board of 1 other company
listed in the 2025 annual accounts, filed on 30-01-2026
- Signing authorityThe articles say who may bind the company, for example by signing a contract.
- Each director alonedeed of 20-02-2023
Permanent representatives 1
Mandates through the years
2 names, the dashed line is todayDirector (not named in the articles)
Statutory manager
BoardEarliermandate already running before its first mention
Mandates as a list
-
- Manager (not named in the articles), appointed by deed of 17-02-2014, until 20-02-2023
- Director (not named in the articles), appointed by deed of 20-02-2023, still in office
-
- Statutory manager, until 17-02-2014
Control
Parent
Equity €2.8m
Profit €91,699 in 2025 (profit €136,259 in 2024)
Source: accounts 30-06-2025
99%
This company
CASSIPHARMA
Equity €217,796
Profit €8,177 in 2025
Capital
- Contribution
- €7,844.54
- Shares
- 100
- Contribution per share
- €78.45
- Equity per share
- €2,178 in 2025
- Source
- 2025 annual accounts
Owners through the years
as the annual accounts name themOwners as a list
-
- 2015 to 2025: 99%
Source: lists of holdings in the owners' accounts
Articles of association
deed of 20-02-2023 (in Dutch)- DurationMost companies exist for an unlimited period, until they are dissolved.
- Unlimited
- Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
- Last Friday of December
Capital transactions
Capital over time
- 20-02-2023 Converted to available equity
- 14-12-2022 Capital stated in the deed · €18,600 · 100 shares